Jin X, Nguyen D, Zhang W W, Kyritsis A P, Roth J A
Department of Thoracic and Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Cancer Res. 1995 Aug 1;55(15):3250-3.
The p16INK4 (MTS1) gene has many features of a tumor suppressor gene. It maps to 9p21, a region of frequent loss of heterozygosity in a variety of tumor types. It encodes an inhibitor of cyclin-dependent kinase 4, and its homozygous deletion is common in tumor-derived cell lines. To examine its tumor suppressive function and its potential in cancer gene replacement therapy, wild-type p16INK4 was expressed in an adenovirus-derived gene delivery system and introduced into lung cancer cell lines that do not express p16INK4. Expression of the introduced p16INK4 blocked tumor cell entry into S phase of the cell cycle and inhibited tumor proliferation both in vitro and in vivo. These observations strongly support that p16INK4 is a tumor suppressor gene and is a candidate for cancer gene replacement therapy.
p16INK4(MTS1)基因具有许多肿瘤抑制基因的特征。它定位于9p21,这是多种肿瘤类型中常发生杂合性缺失的区域。它编码细胞周期蛋白依赖性激酶4的抑制剂,其纯合缺失在肿瘤来源的细胞系中很常见。为了检测其肿瘤抑制功能及其在癌症基因替代疗法中的潜力,野生型p16INK4在腺病毒衍生的基因递送系统中表达,并导入不表达p16INK4的肺癌细胞系中。导入的p16INK4的表达阻断了肿瘤细胞进入细胞周期的S期,并在体外和体内均抑制了肿瘤增殖。这些观察结果有力地支持了p16INK4是一种肿瘤抑制基因,并且是癌症基因替代疗法的候选基因。